1 Sleep duration irregularity and risk for incident cardiovascular disease in the UK Biobank

Tianyi Huang,¹ Sina Kianersi,² Heming Wang,^{2,3} Kaitlin S. Potts,² Raymond Noordam,⁴ Tamar
 Sofer,^{2,5,6} Martin K. Rutter,^{7,8} Susan Redline^{2,9}

4

- ¹Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National
 Institute on Aging, Baltimore, MD, USA
- ²Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's
 Hospital, Boston, MA, USA
- ⁹ ³Broad Institute of MIT and Harvard, Cambridge, MA, USA
- ⁴Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University
- 11 Medical Center, Leiden, The Netherlands
- ⁵Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
- ⁶Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- ⁷Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences,
 University of Manchester, Manchester, UK
- ⁸Diabetes, Endocrinology and Metabolism Centre, Manchester Royal Infirmary, Manchester
- 17 University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester
- 18 Academic Health Science Centre, Manchester, UK
- ⁹Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA

- 21 Corresponding author:
- 22 Tianyi Huang, MSc, ScD
- 23 251 Bayview Blvd., NIH Biomedical Research Center, Ste. 100, Room 09C216, Baltimore, MD
- 24 21224
- 25 Phone: (410) 558-8388
- 26 Email: <u>tianyi.huang@nih.gov</u>
- 27
- 28
- 29
- 30
- 50
- 31
- 32

33 Abstract

34 **Background:** Emerging evidence supports a link between circadian disruption as measured by

higher night-to-night variation in sleep duration and increased risk of cardiovascular disease
 (CVD). It remains unclear whether this association varies by CVD types or may be modified by

37 average sleep duration and genetic risk for CVD.

38 Methods: Our prospective analysis included 86,219 UK Biobank participants who were free

from CVD when completing 7 days of accelerometer measurement in 2013-2016. Sleep

40 irregularity was evaluated by the standard deviation (SD) of accelerometer-measured sleep

41 duration over 7 days. Incident major CVD events, defined as fatal or nonfatal myocardial

42 infarction (MI) and stroke, were identified through linkage to Hospital Episode Statistics data

43 until May 31, 2022. Multivariable-adjusted Cox proportional hazard models were used to

estimate hazard ratios (HRs) and 95% CIs for associations of sleep duration SD with risk for

- 45 major CVD events overall and for MI and stroke separately.
- 46 **Results:** We documented 2,310 incident cases of major CVD events (MI: 1,183, stroke: 1,175)
- 47 over 636,258 person-years of follow-up. After adjusting for sociodemographic factors and family

48 history of CVD, the HR (95% CI) associated with a 1-hour increase in sleep duration SD was

49 1.19 (1.10, 1.27) for CVD (p-trend<0.0001), 1.23 (1.11, 1.35) for MI (p-trend<0.0001), and 1.17

50 (1.05, 1.29) for stroke (p-trend=0.003). Additional adjustment for lifestyle factors, co-morbidities

and sleep-related factors modestly attenuated these associations. Higher sleep irregularity was

52 associated with higher CVD risk irrespective of genetic risk (p-interaction=0.43), but this

- 53 association was stronger among individuals with longer average sleep duration >8 hours (p-
- 54 interaction=0.006)

55 **Conclusions:** Higher night-to-night variation in accelerometer-measured sleep duration was

associated with consistently higher risks for major CVD events. The association did not seem to

57 be modified by genetic risk for CVD and was more pronounced in long sleepers.

58 **Acknowledgements:** This research was supported by NIH grant R01HL155395, UK Biobank

59 project 85501 and the Intramural Research Program of the NIH, National Institute on Aging. SK

60 was supported by the American Heart Association Postdoctoral Fellowship (24POST1188091).

61 Introduction

Sleep health is increasingly recognized as a crucial component of a healthy lifestyle 62 especially for promoting cardiovascular well-being. Numerous prospective epidemiologic studies 63 have linked self-reported short and long sleep duration with higher cardiovascular disease 64 65 (CVD) incidence and mortality.¹ Recent results based on objective sleep assessment or Mendelian randomization also support increased CVD risk and mortality associated with short 66 sleep, although the evidence for long sleep duration is weaker and less consistent.²⁻⁴ Built upon 67 the mounting evidence, the American Heart Association in 2022 updated the construct of 68 69 cardiovascular health from Life's Simple 7 to Life's Essential 8, highlighting the role of sleep health in CVD prevention and focusing on advocating 7-8 hours of habitual sleep.⁵ 70 71 Notably, the mean level of sleep duration, either estimated by self-reports or averaged across multiple nights of objective monitoring, only captures one aspect of sleep health.^{6,7} 72 73 Maintaining consistent sleep-wake cycles is essential for achieving restful, restorative sleep and 74 synchronizing internal circadian rhythms with the social and natural environment. Growing 75 evidence suggests that night-to-night variability in sleep duration, independent of mean sleep duration, is a novel risk factor for cardiometabolic disease and mortality.⁸⁻¹² In the Multi-Ethnic 76 77 Study of Atherosclerosis (MESA), we reported that higher sleep duration irregularity measured by 7-day standard deviation (SD) in actigraphy-based sleep duration was significantly 78 79 associated with greater subclinical atherosclerotic burden and higher CVD risk after accounting for traditional CVD risk factors and average sleep duration.^{8,9} However, the modest sample size 80 81 in MESA constrained our ability to fully explore potential heterogeneity in the association 82 between sleep duration irregularity and CVD risk by major CVD types. It also remains unclear 83 whether sleep duration irregularity, a behavior amenable to modification, may interact with genetic susceptibility to CVD or average sleep duration to influence CVD risk. 84 Leveraging the large-scale accelerometer-measured sleep data from the UK Biobank, 85

86 we evaluated the prospective associations of 7-day variability in sleep duration with incidence of

major adverse cardiovascular events overall and separately for myocardial infarction (MI) and
stroke. We hypothesized that higher variability in sleep duration would exacerbate CVD risk
similarly for MI and stroke, with stronger associations in individuals with a greater genetic
predisposition to CVD or shorter average sleep duration.

91 <u>Methods</u>

92 Study population. The UK Biobank is a large prospective cohort study initiated in 2006-2010, when over 500,000 participants aged 40-69 years completed baseline physical, 93 sociodemographic, and medical assessments in one of 22 centers in the UK.¹³ Participants 94 95 were prospectively followed for occurrence of a wide range of health outcomes, with collection 96 of additional exposure and phenotypic information through further assessment. In 2013-2015, a subsample of 103,712 participants completed an accelerometer study over a 7-day period.¹⁴ 97 Our analysis included 92,884 participants who provided ≥5 days of accelerometer sleep data. Of 98 99 these, we further excluded participants with indicators for poor data quality (e.g., insufficient wear time; n=3,355), extreme sleep values (e.g., average sleep duration <3 hours or >12 hours 100 101 or sleep duration SD >4 hours; n=114), pre-existing CVD prior to the end of accelerometer assessment (n=3,193), or loss to follow-up (n=3), leaving 86,219 for analysis. The UK Biobank 102 103 received approval by the NHS North-West Multi-Centre Research Ethics Committee. All participants provided written informed consent. The present study was completed under the UK 104 Biobank project 85501. 105

Sleep assessment. Between 2013-2015, participants who provided a valid email address were invited to wear a wrist accelerometer (Axivity AX3) for 7 days.¹⁴ A total of 103,712 participants returned the data, which were further processed by the R package GGIR consistent with prior research.^{15,16} Sleep periods and episodes were identified based on 5-second epoch time-series accelerometer signals, and determined as the longest block of combined inactivity bouts lasting \geq 30 min. This algorithm has been validated against polysomnography to accurately detect sleep periods in the absence of sleep diary records.¹⁷ For each participant, we

113 calculated the mean and SD of sleep duration across all available days, and the sleep duration 114 SD was used as the measure for sleep duration irregularity. Sleep efficiency was defined as proportion of sleep duration within the sleep period window (i.e., the time between the start and 115 end of the longest inactivity block). 116 117 At UK Biobank enrollment (2.8 to 9.7 years prior to the accelerometer study), participants also self-reported several habitual sleep symptoms or patterns, with each assessed 118 using a single, representative question carefully chosen from commonly used instruments. 119 120 These sleep metrics included sleep duration, insomnia symptoms, chronotype, snoring and davtime sleepiness.¹⁸ Sleep apnea was identified through a combination of self-reported 121 diagnosis and medical records.¹⁹ 122 123 Ascertainment of CVD events. Incidence of major CVD events was defined as the first 124 occurrence of MI or stroke that resulted in hospitalization or death. Hospital admissions were 125 identified through linkage to the Hospital Episode Statistics, and date of death was identified 126 based on death certificates from the National Death Register. Classification of fatal and nonfatal CVD events was recorded using the International Classification of Diseases, Tenth Revision 127 (ICD-10). We considered ICD-10 codes I21-23 for MI and I60-64 for stroke. 128 129 Statistical analysis. For each participant, we calculated person-time of follow-up from the end date of the accelerometer study until the earliest date of major CVD events, death, or end of 130 follow-up (May 31, 2022). Cox proportional hazards regression was used to estimate the 131 132 association between sleep duration SD and risk of developing CVD events over follow-up. We 133 did not detect significant deviation from the proportional hazards assumption by testing the time-134 by-exposure interaction (p for interaction=0.36). Sleep duration SD was modeled as a 135 continuous variable (per 1-hour) as well as in categories (≤30 [ref], 31-45, 46-60, 61-90, >90 min). The primary model adjusted for age, sex, self-reported race and ethnicity, Townsend 136 137 deprivation index, work schedules, and family history of CVD. Lifestyle, co-morbidities and sleep disturbances may be consequences of irregular sleep duration, therefore acting in the pathway 138

linking sleep duration SD and CVD risk. To avoid potential overadjustment,²⁰ we considered
these covariates in separate multivariable models. In the second model, we further controlled for
BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of
hypertension, dyslipidemia, diabetes and depression. We additionally added to the third model
objectively-measured average sleep duration and sleep efficiency, self-reported insomnia
symptoms, chronotype and sleepiness, and clinically diagnosed sleep apnea. All analyses were
performed for major CVD events overall and for MI and stroke separately.

To test the robustness of the results, we performed several sensitivity analyses. First, 146 147 given that the COVID-19 pandemic may have disrupted healthcare, impacting cardiovascular 148 testing and diagnosis and resulting in outcome misclassification and potentially biased associations,²¹ we repeated the analysis with the end of follow-up as March 23, 2020, the start 149 150 of the UK national lockdown. Second, we excluded CVD events occurring within the first year 151 after the accelerometer study to assess the impact of preclinical CVD and symptoms on sleep 152 duration irregularity (i.e., reverse causation). Third, considering that variation in sleep schedules 153 between weekdays versus weekend (e.g., weekend catch-up sleep) is an important contributor to day-to-day variability in sleep duration across the week ²², we assessed whether the 154 155 observed associations for sleep duration irregularity persisted beyond weekday-weekend 156 variation by focusing on sleep duration SD across weekdays only. Fourth, we examined the associations separately for ischemic and hemorrhagic strokes, as these stroke subtypes may 157 have distinct etiologic origins.²³ 158

We conducted subgroup analysis by age, sex, race, average sleep duration, polygenic risk score (PRS) for CVD, and family history of CVD based on the primary multivariable model. Subgroup heterogeneity was evaluated by the likelihood ratio test of the multiplicative interaction with the continuous sleep duration SD. Of *a priori* interest, we examined the joint associations between sleep duration SD (\leq 30, 31-45, 46-60, 61-90, >90 min) and PRS (low, medium, high) or average sleep duration (<7, 7-8, >8 hrs) with CVD outcomes. Participants with

sleep duration SD <30 min and low PRS or 7-8 hrs of average sleep duration were used as the
reference group in the joint analyses. All statistical analyses were performed using SAS version
9.4 (SAS Institute).

168 <u>Results</u>

169 Of 86,219 participants, the mean (SD) for 7-day SD in sleep duration was 56 (33) 170 minutes, with 25,434 (29.5%) having sleep duration SD>60 minutes. Participants with higher sleep duration irregularity, assessed by sleep duration SD, tended to be younger, female, non-171 172 white, socioeconomically disadvantaged and employed, especially in occupations requiring shift 173 work, and were more likely to have higher BMI and currently smoke (**Table 1**). Family history of 174 CVD was slightly less common in participants with higher sleep duration SD, but no clear 175 difference was observed when genetic risk for CVD was assessed by PRS. Although the 176 prevalence of metabolic disorders (dyslipidemia, hypertension, diabetes) did not differ 177 appreciably across categories of sleep duration SD, the prevalence of depression was higher 178 among participants with greater sleep duration SD. With increasing sleep duration SD, there 179 was a notable trend towards shorter objective sleep duration, particularly among those with sleep duration SD>90 minutes. Additionally, irregular sleepers exhibited lower sleep efficiency 180 181 and were more likely to self-report as evening chronotypes.

182 Associations of sleep duration irregularity and cardiovascular disease risk

Over 636,258 person-years of follow-up (median: 7.5 years), 2,310 participants 183 184 developed a major CVD event (1,183 MI and 1,175 stroke). After adjusting for 185 sociodemographic factors and family history of CVD, the HR (95% CI) for major CVD events 186 was 1.10 (0.97, 1.26) for those with a sleep duration SD of 31-45 minutes, 1.19 (1.04, 1.37) for 187 46-60 minutes, 1.33 (1.15, 1.53) for 61-90 minutes, and 1.40 (1.18, 1.65) for >90 minutes, compared with participants with a sleep duration SD \leq 30 minutes (p for trend<0.0001; **Table 2**). 188 189 Similar positive associations were observed for MI and stroke separately. The HR (95% CI) associated with a 1-hour increase in sleep duration SD was 1.19 (1.10, 1.27) for CVD, 1.23 190

191 (1.11, 1.35) for MI, and 1.17 (1.05, 1.29) for stroke. Further adjustment for lifestyle factors, co-192 morbidities and sleep-related factors only modestly attenuated the associations. For example, the HR (95% CI) for major CVD events per 1-hour increment in sleep duration SD was 1.15 193 (1.07, 1.24) after further adjusting for lifestyle factors and co-morbidities (p for trend=0.0001) 194 195 and 1.13 (1.05, 1.22) after additionally controlling for sleep-related factors (p for trend=0.001). 196 Sensitivity analyses We observed somewhat stronger associations when the analysis was censored at the 197 198 start of the UK COVID-19 lockdown (Supplemental Table 1). For example, the HR (95% CI) for 199 CVD after adjustment for sociodemographic factors and family history of CVD was 1.15 (0.98, 200 1.36) for sleep duration SD of 31-45 minutes, 1.28 (1.08, 1.51) for 46-60 minutes, 1.42 (1.19, 201 1.69) for 61-90 minutes, and 1.51 (1.23, 1.85) for >90 minutes, compared with sleep duration 202 SD ≤30 minutes (p for trend<0.0001). Slightly weaker but significant positive associations were 203 observed in sensitivity analyses excluding CVD events diagnosed within the first year after the sleep assessment (Supplemental Table 2) or only evaluating sleep duration variability across 204 205 weekdays (**Supplemental Table 3**). When examining stroke risk by type, the higher stroke risk associated with irregular sleep duration was primarily attributed to ischemic stroke rather than 206 207 hemorrhagic stroke (Supplemental Table 4).

208 Subgroup associations

The higher CVD risk associated with irregular sleep duration was more pronounced 209 210 among participants ≥ 60 years versus < 60 years (p-interaction=0.04) and among participants 211 with longer average sleep duration >8 hours (p-interaction=0.006; Table 3). We observed a 212 stronger positive association between sleep duration irregularity and CVD risk among 213 participants with a family history of CVD compared to those without the history (pinteraction=0.03). However, such potential gene-sleep interactions were not observed when 214 215 genetic predisposition was assessed by PRS (p-interaction=0.43), and irregular sleep duration was associated with higher CVD risk regardless of the PRS for CVD. There was no significant 216

difference in the association by sex (p-interaction=0.09) or race (p-interaction=0.42), although
the race-stratified analysis was underpowered. These subgroup differences remained largely
the same when MI and stroke were examined individually, except that the association for stroke
did not differ by family history of CVD and was significantly stronger in men than in women
(Supplemental Table 5).

Joint associations

Irregular sleep duration was consistently associated with increases in CVD risk across 223 224 tertiles of PRS for CVD (Figure 1a). Compared with individuals with low genetic risk and a sleep 225 duration SD<30 min, the highest CVD risks were observed in individuals with high genetic risk and a sleep duration SD 61-90 minutes (HR: 2.52; 95% CI: 1.94, 3.28) or >90 minutes (HR: 226 227 2.39; 95% CI: 1.78, 3.22). Further, higher risks for MI or stroke associated with irregular sleep 228 duration were observed across various genetic risk categories for MI or stroke, except for 229 individuals with low genetic risk for stroke, where no clear association was found 230 (Supplemental Figure 1). Compared with individuals with a sleep duration SD \leq 30 min and an optimal sleep duration of 7-8 hours, the elevated CVD risk associated with a large sleep 231 duration SD >90 minutes was more pronounced in long sleepers >8 hrs (HR: 1.95; 95% CI: 232 233 1.29, 2.93) than in short sleepers <7 hrs (HR: 1.42; 95% CI: 1.15, 1.77; Figure 1b). The joint association patterns were similar for MI and stroke individually (Supplemental Figure 2). 234 Discussion 235 236 This prospective study in the UK Biobank shows higher CVD risks among individuals

with irregular sleep duration after accounting for established CVD risk factors. The observed
increase in CVD risk associated with irregular sleep duration was similar for MI and stroke.
Although irregular sleep duration was consistently associated with higher CVD risk irrespective
of the genetic risk profile or the average sleep duration, the association was more pronounced
among individuals with sleep duration longer than 8 hours.

Consistent with prior studies linking sleep irregularity with higher risks for CVD⁸ and total 242 mortality¹⁰⁻¹² as well as with CVD risk factors including atherosclerotic development,⁹ metabolic 243 syndrome²⁴ and diabetes,²⁵ our findings provide further evidence supporting the congruent 244 associations of irregular sleep duration with risk of MI and stroke, particularly ischemic stroke. 245 246 This suggests that irregular sleep duration may modulate common pathways leading to 247 ischemic cardiovascular events. These pathways include dysregulation of blood pressure, glucose/lipid metabolism, inflammation, endothelial function, and thrombotic events induced by 248 circadian disruption,²⁶⁻³¹ as well as adverse effects of intermittent sleep curtailment on 249 sympathetic and hormonal activities.³²⁻³⁴ Given that irregular sleep duration can occur on a daily, 250 habitual basis, the resulting biologic changes may act as triggers for adverse cardiovascular 251 252 events, significantly increasing the chance of developing CVD events over the long term. More 253 direct evidence is needed to fully understand the mechanisms underlying the association 254 between irregular sleep duration and CVD risk.

Of note, the association observed in the current study was more modest compared to 255 our prior investigation in MESA.⁸ Specifically, the HR (95% CI) for CVD was 1.19 (1.10, 1.27) in 256 the UK Biobank and 1.41 (1.12, 1.79) in MESA. While the smaller sample size in MESA may 257 258 contribute to less accurate estimates, key differences between the cohorts could also explain 259 this. For example, MESA included older individuals (mean age: 69 vs 62 years), and our subgroup analysis suggests that older individuals may be more vulnerable to the negative 260 261 cardiovascular effects of irregular sleep duration. The prevalence of irregular sleep duration also 262 differed, with 39.5% in MESA having a 7-day sleep duration SD >90 min compared to 10.4% in 263 the UK Biobank. Further, the UK Biobank analysis included the COVID-19 period, which, 264 according to sensitivity analysis, led to a weaker overall association. Greater misclassification of CVD outcomes due to delayed or missed diagnostic testing during the COVID-19 period,²¹ as 265 266 well as inaccuracy of using data from 2013-2015 to reflect pandemic sleep duration irregularity when many were staying at home, may have both attenuated the observed association. 267

268 Consistent with our initial hypothesis, irregular sleep duration was more strongly 269 associated with CVD risk among individuals with a family history of CVD, an indirect measure 270 for inherited susceptibility. However, such a gene-sleep interaction was not present when PRS was used as the direct, quantitative measure for genetic susceptibility. A positive association 271 272 between irregular sleep duration and CVD risk was consistently observed in individuals with low, 273 medium, or high genetic risk, similar to a previous UK Biobank study evaluating gene-sleep interactions for CVD risk based on self-reported sleep traits.¹⁸ The inconsistent findings may be 274 attributed to the fact that PRS and family history represent independent and complementary 275 rather than interchangeable measures for inherited disease susceptibility.³⁵ Family history 276 277 encompasses additional lifestyle and environmental factors shared within families that may 278 influence the associations beyond genetic susceptibility. It is also possible that irregular sleep 279 duration may interact with specific genetic pathways to influence CVD risk. Significant gene-280 sleep interactions may be more likely to be observed with pathway-specific PRS rather than the overall CVD PRS,¹⁹ which requires future investigation. 281

Intriguingly, although shorter sleepers (<7 hours) tended to exhibit greater sleep duration 282 irregularity, longer sleepers (>8 hours) seemed more susceptible to the adverse effects of sleep 283 284 duration irregularity on CVD risk. This suggests that excessive catch-up sleep, which resulted in both longer average sleep duration and larger variability, may not compensate for sleep debt but 285 conversely may lead to circadian dysregulation and increased CVD risk.³⁶ Previous research on 286 287 weekday-weekend differences in sleep duration only found beneficial relationships of shorter, but not longer, weekend catch-up sleep with inflammation and mortality.^{37,38} Our joint analysis 288 289 suggests that irregular sleep duration coupled with long sleep duration conferred the highest 290 CVD risk. Other studies reported that sleep irregularity was a stronger predictor of mortality than either sleep duration¹¹ or sleep apnea.¹² As a result, a recent consensus statement from the 291 292 National Sleep Foundation highlighted the importance of sleep regularity for health and

293 performance,³⁹ calling for increased research and public initiatives to optimize sleep regularity at
294 the population level.

The strengths of the study included the prospective design, large-scale accelerometer 295 296 measurements, systematic identification of incident CVD outcomes through ICD-coded health 297 records, and the availability of important covariates including genetic risk. However, the 298 analytical sample from the UK Biobank included primarily white British participants with relatively high socioeconomic background, potentially limiting the generalizability of our findings 299 300 to other populations. Nonetheless, the consistency with results from the racial and ethnic 301 diverse MESA cohort⁸ suggests that the impact of irregular sleep duration on CVD risk may 302 have broader implications. We relied on accelerometer measurement taken over 7 days to quantify irregular sleep duration, which may not reliably represent long-term habitual sleep 303 304 patterns that are relevant for CVD pathogenesis, particularly during the pandemic. This 305 limitation could weaken the observed associations and may partially explain why stronger 306 associations were observed when the COVID-19 period was excluded from the analysis. 307 Despite the possibility for residual confounding given that many covariates were assessed at the UK Biobank baseline 2.8 to 9.7 years prior to the accelerometer study, it is unlikely that 308 309 misclassification of time-varying covariates (e.g., work schedules) could fully account for the associations observed. Finally, our study was observational by nature, and further evidence is 310 needed to establish the causal relationship between irregular sleep duration and CVD risk. 311 312 In summary, irregular sleep duration as characterized by high day-to-day variation in 313 habitual sleep duration over a 7-day period was associated with higher CVD risk overall as well

as higher risk of MI and stroke individually in the UK Biobank. The association remained robust
after adjustment for a wide variety of factors, did not differ appreciably by genetic risk for CVD,
and was particularly strong in long sleepers and older individuals. These findings underscore
the importance of maintaining consistent sleep duration for cardiovascular health and suggest

- that promoting regular sleep duration may be a novel behavioral strategy for CVD risk reduction
- that should be tested in intervention studies.
- 320
- 321

322 References

- Kwok CS, Kontopantelis E, Kuligowski G, Gray M, Muhyaldeen A, Gale CP, Peat GM,
 Cleator J, Chew-Graham C, Loke YK, et al. Self-Reported Sleep Duration and Quality
 and Cardiovascular Disease and Mortality: A Dose-Response Meta-Analysis. *J Am Heart Assoc.* 2018;7:e008552. doi: 10.1161/jaha.118.008552
- Zhao B, Meng Y, Jin X, Xi W, Ma Q, Yang J, Ma X, Yan B. Association of Objective and Self-Reported Sleep Duration With All-Cause and Cardiovascular Disease Mortality: A Community-Based Study. *J Am Heart Assoc*. 2023;12:e027832. doi:
- 330 10.1161/jaha.122.027832
- Wang S, Li Z, Wang X, Guo S, Sun Y, Li G, Zhao C, Yuan W, Li M, Li X, et al.
 Associations between sleep duration and cardiovascular diseases: A meta-review and meta-analysis of observational and Mendelian randomization studies. *Front Cardiovasc Med*. 2022;9:930000. doi: 10.3389/fcvm.2022.930000
- Daghlas I, Dashti HS, Lane J, Aragam KG, Rutter MK, Saxena R, Vetter C. Sleep
 Duration and Myocardial Infarction. *J Am Coll Cardiol*. 2019;74:1304-1314. doi:
 10.1016/j.jacc.2019.07.022
- Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, Grandner
 MA, Lavretsky H, Perak AM, Sharma G, et al. Life's Essential 8: Updating and
 Enhancing the American Heart Association's Construct of Cardiovascular Health: A
 Presidential Advisory From the American Heart Association. *Circulation*. 2022;146:e18 e43. doi: 10.1161/cir.00000000001078
- Buysse DJ. Sleep health: can we define it? Does it matter? *Sleep*. 2014;37:9-17. doi: 10.5665/sleep.3298
- 7. Chung J, Goodman M, Huang T, Bertisch S, Redline S. Multidimensional sleep health in
 a diverse, aging adult cohort: Concepts, advances, and implications for research and
 intervention. *Sleep Health*. 2021;7:699-707. doi: 10.1016/j.sleh.2021.08.005
- Huang T, Mariani S, Redline S. Sleep Irregularity and Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis. *J Am Coll Cardiol*. 2020;75:991-999. doi: 10.1016/j.jacc.2019.12.054
- Full KM, Huang T, Shah NA, Allison MA, Michos ED, Duprez DA, Redline S, Lutsey PL.
 Sleep Irregularity and Subclinical Markers of Cardiovascular Disease: The Multi-Ethnic
 Study of Atherosclerosis. *J Am Heart Assoc*. 2023;12:e027361. doi:
 10.1161/jaha.122.027361
- Cribb L, Sha R, Yiallourou S, Grima NA, Cavuoto M, Baril AA, Pase MP. Sleep regularity
 and mortality: a prospective analysis in the UK Biobank. *Elife*. 2023;12. doi:
 10.7554/eLife.88359
- Windred DP, Burns AC, Lane JM, Saxena R, Rutter MK, Cain SW, Phillips AJK. Sleep
 regularity is a stronger predictor of mortality risk than sleep duration: A prospective
 cohort study. *Sleep*. 2024;47. doi: 10.1093/sleep/zsad253
- Chung J, Goodman MO, Huang T, Castro-Diehl C, Chen JT, Sofer T, Bertisch SM,
 Purcell SM, Redline S. Objectively regular sleep patterns and mortality in a prospective
 cohort: The Multi-Ethnic Study of Atherosclerosis. *J Sleep Res.* 2024;33:e14048. doi:
 10.1111/jsr.14048
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green
 J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a
 wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12:e1001779.
 doi: 10.1371/journal.pmed.1001779
- 14. Doherty A, Jackson D, Hammerla N, Plötz T, Olivier P, Granat MH, White T, van Hees
 VT, Trenell MI, Owen CG, et al. Large Scale Population Assessment of Physical Activity

274		Liener Writet Warre Associate restarter The LIK Dish and Churchy Disc One
3/1		Using Wrist Worn Accelerometers: The UK Biobank Study. PLoS One.
372	15	2017;12:e0109049. doi: 10.1371/journal.pone.0109049
3/3	10. 16	Vall nees VI, Fally Z, Zhao Jn, neywood J, Milkes E, Sabia S. Package GGIR . 2024.
374	10.	Doubti HS, Lalle Jivi, Wood AR, Vall flees VI, Tyltell J, Deautionit RN, Jeilles AR,
375		in 607 828 individuals provides insights into size dia routien that the Net Commun
570 277		2010:10:3/3 doi: 10.1038/c/1/67.018.08250.7
577 270	17	van Hees VT Sabia S. Jones SE. Wood AP. Anderson KN. Kivimäki M. Eravling TM
370	17.	Pack AL Bucan M Trenell ML et al. Estimating sleep parameters using an accelerometer.
380		without sleep diary. Sci Rep. 2018:8:12975. doi: 10.1038/s41598-018-31266-z
381	18	Fan M Sun D Zhou T Hejanza Y Lv. Li L Oi L Sleep patterns, genetic suscentibility
382	10.	and incident cardiovascular disease: a prospective study of 385 292 UK biobank
383		participants Fur Heart J 2020:41:1182-1189 doi: 10.1093/eurhearti/ebz849
384	19.	Goodman MO, Cade BE, Shah NA, Huang T, Dashti HS, Saxena R, Rutter MK, Libby P.
385		Sofer T. Redline S. Pathway-Specific Polygenic Risk Scores Identify Obstructive Sleep
386		Apnea-Related Pathways Differentially Moderating Genetic Susceptibility to Coronary
387		Artery Disease. <i>Circ Genom Precis Med</i> . 2022;15:e003535. doi:
388		10.1161/circgen.121.003535
389	20.	Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment
390		in epidemiologic studies. <i>Epidemiology</i> . 2009;20:488-495. doi:
391		10.1097/EDE.0b013e3181a819a1
392	21.	Einstein AJ, Shaw LJ, Hirschfeld C, Williams MC, Villines TC, Better N, Vitola JV, Cerci
393		R, Dorbala S, Raggi P, et al. International Impact of COVID-19 on the Diagnosis of Heart
394		Disease. J Am Coll Cardiol. 2021;77:173-185. doi: 10.1016/j.jacc.2020.10.054
395	22.	Leger D, Richard JB, Collin O, Sauvet F, Faraut B. Napping and weekend catchup sleep
396		do not fully compensate for high rates of sleep debt and short sleep at a population level
397		(in a representative nationwide sample of 12,637 adults). <i>Sleep Med</i> . 2020;74:278-288.
398		doi: 10.1016/j.sleep.2020.05.030
399	23.	Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic
400		stroke: incidence, prevalence, mortality, and risk factors. <i>Neurol Clin</i> . 2008;26:871-895,
401	0.4	VII. doi: 10.1016/j.ncl.2008.07.003
402	24.	Huang I, Redline S. Cross-sectional and Prospective Associations of Actigraphy-
403		Assessed Sleep Regularity with Metabolic Abnormalities: The Multi-Ethnic Study of
404	05	Atheroscierosis. Diabetes Care. 2019;42:1422-1429. doi: 10.2337/dc19-0596
405	25.	Kianersi S, Wang H, Soler T, Noordam R, Phillips A, Rutter MK, Redine S, Huang T.
406		Association between Accelerometer-measured megular Sleep Duration and Type 2 Disbetes Disk: A Drespective Cabert Study in the LIK Disbetes Core, 2024, doi:
407		10 2227/do24 0212
408	26	10.2557/0624-0215 Smolensky MH, Hermida PC, Portaluppi E, Circadian mechanisms of 24 hour blood
409	20.	pressure regulation and patterning. Sleen Med Rev. 2017:33:4-16. doi:
410 //11		10 1016/i smrv 2016 02 003
411 412	27	Poggiogalle F. Jamshed H. Peterson CM. Circadian regulation of ducose linid and
412	21.	energy metabolism in humans <i>Metabolism</i> 2018:84:11-27 doi:
414		10 1016/i metabol 2017 11 017
415	28	Westgate F.J. Cheng Y Reilly DF Price TS Walisser JA Bradfield CA FitzGerald GA
416	20.	Genetic components of the circadian clock regulate thrombogenesis in vivo Circulation
417		2008:117:2087-2095. doi: 10.1161/circulationaha.107.739227
418	29.	Lo EH, Faraci FM. Circadian Mechanisms in Cardiovascular and Cerebrovascular
419		Disease. Circ Res. 2024;134:615-617. doi: 10.1161/circresaha.124.324462
420	30.	Man AWC, Li H, Xia N. Circadian Rhythm: Potential Therapeutic Target for
421		Atherosclerosis and Thrombosis. Int J Mol Sci. 2021;22. doi: 10.3390/ijms22020676

422	31.	McAlpine CS, Swirski FK. Circadian Influence on Metabolism and Inflammation in
423		Atherosclerosis. Circ Res. 2016;119:131-141. doi: 10.1161/circresaha.116.308034
424	32.	Tobaldini E, Costantino G, Solbiati M, Cogliati C, Kara T, Nobili L, Montano N. Sleep,
425		sleep deprivation, autonomic nervous system and cardiovascular diseases. <i>Neurosci</i>
426		<i>Biobehav Rev</i> . 2017;74:321-329. doi: 10.1016/j.neubiorev.2016.07.004
427	33.	Leproult R, Van Cauter E. Role of sleep and sleep loss in hormonal release and
428		metabolism. <i>Endocr Dev</i> . 2010;17:11-21. doi: 10.1159/000262524
429	34.	Huang T, Poole EM, Vetter C, Rexrode KM, Kubzansky LD, Schernhammer E, Rohleder
430		N, Hu FB, Redline S, Tworoger SS. Habitual sleep quality and diurnal rhythms of salivary
431		cortisol and dehydroepiandrosterone in postmenopausal women.
432		Psychoneuroendocrinology. 2017;84:172-180. doi: 10.1016/j.psyneuen.2017.07.484
433	35.	Mars N, Lindbohm JV, Della Briotta Parolo P, Widén E, Kaprio J, Palotie A, Ripatti S.
434		Systematic comparison of family history and polygenic risk across 24 common diseases.
435		<i>Am J Hum Genet</i> . 2022;109:2152-2162. doi: 10.1016/j.ajhg.2022.10.009
436	36.	Putilov AA. Sleep during "lockdown" highlighted the need to rethink the concept of
437		weekend catch-up sleep. Sleep Breath. 2022;26:2001-2007. doi: 10.1007/s11325-021-
438		02492-z
439	37.	Yoshiike T, Kawamura A, Utsumi T, Matsui K, Kuriyama K. A prospective study of the
440		association of weekend catch-up sleep and sleep duration with mortality in middle-aged
441		adults. Sleep Biol Rhythms. 2023;21:409-418. doi: 10.1007/s41105-023-00460-6
442	38.	Han KM, Lee HJ, Kim L, Yoon HK. Association between weekend catch-up sleep and
443		high-sensitivity C-reactive protein levels in adults: a population-based study. Sleep.
444		2020;43. doi: 10.1093/sleep/zsaa010
445	39.	Sletten TL, Weaver MD, Foster RG, Gozal D, Klerman EB, Rajaratnam SMW,
446		Roenneberg T, Takahashi JS, Turek FW, Vitiello MV, et al. The importance of sleep
447		regularity: a consensus statement of the National Sleep Foundation sleep timing and
448		variability panel. <i>Sleep Health</i> . 2023;9:801-820. doi: 10.1016/j.sleh.2023.07.016

Table 1. C	haracteristics	of the study	population	by category	of sleep	duration	irregularity
------------	----------------	--------------	------------	-------------	----------	----------	--------------

		7-day sleep	duration stand	ard deviation	
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min
Ν	12764	26018	22003	16503	8931
Sociodemographic factors					
Age at sleep study	63.7 (7.7)	63.0 (7.8)	62.3 (7.8)	61.5 (7.8)	60.5 (8.0)
Female, %	54	57	58	60	58
White, %	98	98	97	96	95
Townsend Deprivation Index	-2.0 (2.6)	-1.9 (2.7)	-1.7 (2.8)	-1.5 (2.9)	-1.3 (3.0)
Work schedules					
Employed no shiftwork, %	46	49	51	53	52
Employed with shiftwork, %	5	6	7	10	13
Retired/Do not work, %	49	45	42	38	35
Genetic factors					
Family history of CVD, %	61	61	60	60	57
PRS for CVD	-0.18 (0.96)	-0.16 (0.98)	-0.16 (0.97)	-0.15 (0.97)	-0.15 (0.97)
PRS for MI	-0.22 (0.95)	-0.21 (0.95)	-0.20 (0.95)	-0.19 (0.96)	-0.21 (0.95)
PRS for stroke	-0.11 (0.92)	-0.08 (0.93)	-0.08 (0.93)	-0.06 (0.93)	-0.06 (0.93)
Lifestyle factors					
Body mass index, kg/m2	26.2 (4.2)	26.4 (4.4)	26.7 (4.5)	27.1 (4.7)	27.3 (5.0)
Current Smoker, %	5	6	6	8	9
Current alcohol drinker, %	95	95	95	94	93
Healthy diet score	3.2 (1.2)	3.2 (1.2)	3.1 (1.2)	3.1 (1.2)	3.1 (1.3)
Physical activity, MET-hrs/week	34.6 (38.9)	35.0 (39.9)	34.7 (40.5)	34.6 (40.6)	34.7 (40.8)
Clinical factors					
Dislipidemia, %	18	18	17	18	17
Hypertension, %	25	26	26	27	25
Diabetes, %	3	4	4	4	4
Depression status, ¹ %	31	32	35	37	37
Sleep-related factors					
Average sleep duration	7.5 (0.8)	7.4 (0.8)	7.4 (0.8)	7.3 (0.8)	6.6 (1.0)
Sleep duration categories					
<7 hrs, %	26	28	31	37	67
7-8 hrs, %	51	50	48	45	26
>8 hrs, %	23	22	20	18	8
Sleep efficiency	0.77 (0.07)	0.77 (0.07)	0.76 (0.07)	0.75 (0.07)	0.73 (0.09)
Chronotype					
Morning type, %	23	24	24	23	22
Intermediate type, %	70	69	68	67	67
Evening type, %	6	7	8	10	11
Insomnia symptoms					
Never/rarely, %	25	25	25	25	26
Sometimes, %	49	48	48	47	47
Usually, %	26	27	27	28	27
Daytime sleepiness					

Never/rarely, %	79	79	78	77	78
Sometimes, %	19	19	19	20	19
Usually, %	2	2	2	2	3
Sleep apnea, %	1	1	1	1	1

Values are means (SD) for continuous variables and percentages for categorical variables.

¹Based on self-reported depressive symptoms or self-reported clinic visits for depression

		7-day sleep duration standard deviation				Por 1 hour	P-trend
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min	Per i noui	r-trenu
Major cardiovascular events							
Cases	327	691	589	455	248	2310	
Person-years	94088	192004	162509	121711	65945	636258	
Model 1	Ref	1.10 (0.97, 1.26)	1.19 (1.04, 1.37)	1.33 (1.15, 1.53)	1.40 (1.18, 1.65)	1.19 (1.10, 1.27)	<.0001
Model 2	Ref	1.09 (0.95, 1.24)	1.15 (1.01, 1.32)	1.25 (1.08, 1.44)	1.31 (1.11, 1.55)	1.15 (1.07, 1.24)	0.0001
Model 3	Ref	1.09 (0.95, 1.24)	1.15 (1.00, 1.31)	1.24 (1.07, 1.43)	1.27 (1.07, 1.50)	1.13 (1.05, 1.22)	0.001
Myocardial infarction							
Cases	176	331	310	228	138	1183	
Person-years	94454	192993	163280	122333	66255	639316	
Model 1	Ref	0.98 (0.82, 1.18)	1.16 (0.96, 1.40)	1.21 (0.99, 1.48)	1.39 (1.11, 1.74)	1.23 (1.11, 1.35)	<.0001
Model 2	Ref	0.96 (0.80, 1.15)	1.11 (0.92, 1.33)	1.12 (0.92, 1.36)	1.28 (1.02, 1.60)	1.18 (1.07, 1.31)	0.001
Model 3	Ref	0.96 (0.80, 1.15)	1.09 (0.91, 1.31)	1.10 (0.90, 1.34)	1.20 (0.96, 1.51)	1.15 (1.04, 1.27)	0.008
Stroke							
Cases	159	369	290	237	120	1175	
Person-years	94519	192940	163443	122385	66379	639665	
Model 1	Ref	1.21 (1.01, 1.46)	1.21 (1.00, 1.47)	1.44 (1.18, 1.77)	1.43 (1.13, 1.82)	1.17 (1.05, 1.29)	0.003
Model 2	Ref	1.20 (1.00, 1.45)	1.19 (0.98, 1.44)	1.38 (1.13, 1.70)	1.38 (1.08, 1.75)	1.15 (1.03, 1.27)	0.01
Model 3	Ref	1.20 (1.00, 1.45)	1.19 (0.98, 1.44)	1.38 (1.13, 1.70)	1.36 (1.07, 1.74)	1.14 (1.03, 1.27)	0.01

Table 2.	Associations of	f accelerometer-measured sl	eep duration irregulari	ty with incident ca	ardiovascular events in	n the UK Biobank
				· · · · · · · · · · · · · · · · · · ·		

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD

Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

sleep duration megularity al	iu caruiovasculai uis		Jank
	Cases/N	HR (95% CI) ¹	P-int
Age			0.04
<60 yrs	393/31903	1.02 (0.86, 1.20)	
≥60 yrs	1917/54316	1.23 (1.13, 1.33)	
Sex			0.09
Men	1414/36651	1.22 (1.11, 1.33)	
Women	896/49568	1.13 (1.00, 1.27)	
Race			0.42
White	2242/83577	1.19 (1.11, 1.28)	
Non-white	68/2642	1.01 (0.68, 1.51)	
Average sleep duration			0.006
<7 hrs	876/29488	1.07 (0.97, 1.18)	
7-8 hrs	983/39890	1.22 (1.07, 1.40)	
>8 hrs	451/16841	1.52 (1.23, 1.89)	
Family history of CVD			0.03
No	759/34288	1.07 (0.94, 1.22)	
Yes	1551/51931	1.24 (1.14, 1.35)	
PRS ²			0.43
Low	544/28033	1.17 (1.01, 1.36)	
Medium	721/28034	1.34 (1.19, 1.51)	
High	991/28034	1.09 (0.97, 1.22)	

Table 3. Subgroup analysis of the association between accelerometer-measured sleep duration irregularity and cardiovascular disease risk in the UK Biobank

¹Adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD

²Among 84101 participants with genotyping information with additional adjustment of the first three genetic principal components

Figure 1. Risk of incident cardiovascular events according to joint categories of sleep duration irregularity and (a) polygenic risk score for CVD and (b) average sleep duration. Estimates adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD (plus the first three genetic principal components for joint associations with the polygenic risk score).

(a)





(b)

		7-da	y sleep duration stan	dard deviation		Dor 1 hour	D trand
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min	Fei i noui	F-lienu
Major cardiovascul	ar events						
Cases	205	449	393	304	173	1524	
Person-years	69140	140444	119186	89709	50157	468635	
Model 1	Ref	1.15 (0.98, 1.36)	1.28 (1.08, 1.51)	1.42 (1.19, 1.69)	1.51 (1.23, 1.85)	1.24 (1.13, 1.35)	<.0001
Model 2	Ref	1.13 (0.96, 1.34)	1.23 (1.04, 1.46)	1.32 (1.11, 1.58)	1.41 (1.15, 1.72)	1.20 (1.10, 1.31)	<.0001
Model 3	Ref	1.13 (0.96, 1.33)	1.22 (1.03, 1.45)	1.31 (1.09, 1.57)	1.35 (1.10, 1.67)	1.17 (1.07, 1.28)	0.0008
Myocardial infarction	on						
Cases	109	218	213	160	97	797	
Person-years	69323	140940	119576	90017	50329	470185	
Model 1	Ref	1.05 (0.83, 1.32)	1.29 (1.03, 1.63)	1.38 (1.08, 1.76)	1.54 (1.17, 2.03)	1.30 (1.15, 1.46)	<.0001
Model 2	Ref	1.03 (0.82, 1.30)	1.23 (0.98, 1.55)	1.26 (0.99, 1.62)	1.41 (1.07, 1.86)	1.25 (1.11, 1.41)	0.0003
Model 3	Ref	1.02 (0.81, 1.29)	1.21 (0.96, 1.52)	1.23 (0.96, 1.57)	1.30 (0.98, 1.73)	1.20 (1.06, 1.35)	0.004
Stroke							
Cases	101	235	187	152	81	756	
Person-years	69353	140907	119671	90035	50394	470359	
Model 1	Ref	1.22 (0.97, 1.55)	1.24 (0.98, 1.58)	1.46 (1.14, 1.88)	1.47 (1.10, 1.98)	1.19 (1.04, 1.35)	0.009
Model 2	Ref	1.21 (0.96, 1.52)	1.21 (0.95, 1.54)	1.39 (1.08, 1.79)	1.40 (1.05, 1.89)	1.16 (1.02, 1.33)	0.02
Model 3	Ref	1.21 (0.96, 1.53)	1.21 (0.95, 1.55)	1.40 (1.09, 1.81)	1.41 (1.04, 1.90)	1.16 (1.01, 1.33)	0.03

Supplemental Table 1. Associations of accelerometer-measured sleep duration irregularity with incident cardiovascular events in the UK Biobank, censored at the start of the COVID-19 pandemic lockdown (March 23, 2020)

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

Supplemental Table 2. Associations of accelerometer-measured sleep duration irregularity with incident cardiovascular events in the UK Biobank, excluding cases diagnosed in the first year of follow-up

		7-da	y sleep duration stan	dard deviation		Dor 1 hour	D trand
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min	Per i noui	P-trenu
Major cardiovascula	ar events						
Cases	303	613	520	401	203	2040	
Person-years	94060	191940	162456	121669	65916	636041	
Model 1	Ref	1.06 (0.92, 1.21)	1.14 (0.99, 1.31)	1.27 (1.09, 1.47)	1.24 (1.04, 1.48)	1.14 (1.06, 1.23)	0.001
Model 2	Ref	1.04 (0.91, 1.20)	1.10 (0.96, 1.27)	1.20 (1.03, 1.39)	1.17 (0.98, 1.40)	1.11 (1.03, 1.20)	0.01
Model 3	Ref	1.04 (0.91, 1.19)	1.10 (0.95, 1.26)	1.18 (1.02, 1.38)	1.13 (0.94, 1.36)	1.09 (1.01, 1.19)	0.03
Myocardial infarctic	n						
Cases	164	299	271	199	111	1044	
Person-years	94431	192949	163240	122300	66232	639152	
Model 1	Ref	0.95 (0.79, 1.15)	1.09 (0.90, 1.32)	1.14 (0.92, 1.40)	1.21 (0.95, 1.54)	1.17 (1.05, 1.30)	0.004
Model 2	Ref	0.93 (0.77, 1.13)	1.04 (0.85, 1.26)	1.05 (0.85, 1.29)	1.11 (0.87, 1.41)	1.13 (1.01, 1.26)	0.03
Model 3	Ref	0.93 (0.77, 1.12)	1.02 (0.84, 1.24)	1.03 (0.84, 1.27)	1.05 (0.82, 1.34)	1.10 (0.98, 1.23)	0.1
Stroke							
Cases	147	322	260	211	101	1041	
Person-years	94495	192891	163410	122354	66359	639509	
Model 1	Ref	1.14 (0.94, 1.39)	1.18 (0.96, 1.44)	1.39 (1.13, 1.72)	1.31 (1.02, 1.69)	1.14 (1.02, 1.27)	0.02
Model 2	Ref	1.13 (0.93, 1.38)	1.16 (0.95, 1.42)	1.34 (1.09, 1.66)	1.26 (0.98, 1.63)	1.12 (1.00, 1.25)	0.04
Model 3	Ref	1.14 (0.93, 1.38)	1.16 (0.95, 1.42)	1.34 (1.08, 1.66)	1.25 (0.97, 1.63)	1.11 (0.99, 1.25)	0.06

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

Supplemental Table 3. Associations of accelerometer-measured sleep duration irregularity on weekdays with incident cardiovascular events in the UK Biobank

	Der 1 hour	Ditrond					
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min	Per i nour	P-trend
Major cardiovascu	lar events						
Cases	277	408	380	508	411	1984	
Person-years	84861	122075	111436	138939	96557	553867	
Model 1	Ref	1.00 (0.86, 1.17)	1.03 (0.88, 1.20)	1.09 (0.94, 1.26)	1.24 (1.07, 1.45)	1.18 (1.09, 1.28)	<.0001
Model 2	Ref	1.00 (0.85, 1.16)	1.01 (0.86, 1.17)	1.04 (0.90, 1.20)	1.15 (0.99, 1.35)	1.13 (1.04, 1.22)	0.003
Model 3	Ref	1.00 (0.85, 1.16)	1.00 (0.86, 1.17)	1.03 (0.89, 1.20)	1.14 (0.97, 1.33)	1.12 (1.03, 1.21)	0.005
Myocardial infarction	on						
Cases	141	203	178	263	205	990	
Person-years	85221	122592	111986	139666	97108	556573	
Model 1	Ref	0.99 (0.80, 1.23)	0.96 (0.77, 1.20)	1.13 (0.92, 1.39)	1.26 (1.02, 1.57)	1.19 (1.06, 1.32)	0.002
Model 2	Ref	0.98 (0.79, 1.21)	0.93 (0.74, 1.16)	1.06 (0.86, 1.30)	1.14 (0.92, 1.42)	1.11 (1.00, 1.24)	0.05
Model 3	Ref	0.98 (0.79, 1.22)	0.92 (0.74, 1.15)	1.05 (0.85, 1.29)	1.12 (0.90, 1.39)	1.10 (0.98, 1.23)	0.09
Stroke							
Cases	139	214	212	253	214	1032	
Person-years	85272	122666	111941	139716	97129	556725	
Model 1	Ref	1.04 (0.84, 1.29)	1.13 (0.91, 1.40)	1.06 (0.86, 1.30)	1.24 (1.00, 1.54)	1.18 (1.06, 1.31)	0.002
Model 2	Ref	1.03 (0.83, 1.28)	1.11 (0.90, 1.38)	1.02 (0.83, 1.26)	1.18 (0.95, 1.46)	1.14 (1.02, 1.27)	0.02
Model 3	Ref	1.03 (0.83, 1.28)	1.11 (0.90, 1.38)	1.02 (0.83, 1.26)	1.17 (0.94, 1.45)	1.14 (1.02, 1.27)	0.02

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

Supplemental Table 4. Associations of accelerometer-measured sleep duration irregularity with risk of ischemic and hemorrhagic stroke in the UK Biobank

	7-day sleep duration standard deviation					Per 1 hour	P_trond
	<30 min	30-44 min	45-59 min	60-89 min	≥90 min	Fei I noui	r-trenu
Ischemic stroke							
Cases	118	266	211	186	98	879	
Person-years	94519	192940	163443	122385	66379	639665	
Model 1	Ref	1.18 (0.95, 1.47)	1.20 (0.96, 1.50)	1.54 (1.22, 1.94)	1.59 (1.21, 2.08)	1.24 (1.10, 1.39)	0.0003
Model 2	Ref	1.17 (0.94, 1.46)	1.17 (0.93, 1.47)	1.47 (1.17, 1.86)	1.51 (1.16, 1.99)	1.21 (1.08, 1.36)	0.001
Model 3	Ref	1.18 (0.95, 1.46)	1.18 (0.94, 1.48)	1.48 (1.17, 1.87)	1.52 (1.15, 2.00)	1.21 (1.08, 1.37)	0.002
Hemorrhagic stroke							
Cases	44	105	81	55	24	309	
Person-years	94519	192940	163443	122385	66379	639665	
Model 1	Ref	1.23 (0.87, 1.75)	1.20 (0.83, 1.74)	1.18 (0.79, 1.76)	1.02 (0.62, 1.68)	0.97 (0.78, 1.21)	0.79
Model 2	Ref	1.22 (0.86, 1.74)	1.19 (0.82, 1.72)	1.15 (0.77, 1.72)	1.00 (0.61, 1.65)	0.96 (0.77, 1.20)	0.72
Model 3	Ref	1.21 (0.85, 1.73)	1.17 (0.81, 1.70)	1.13 (0.75, 1.68)	0.96 (0.58, 1.60)	0.94 (0.75, 1.18)	0.61

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

	Myocardial infarction			Stroke		
	Cases/N	HR (95% CI) ¹	P-int	Cases/N	HR (95% CI) ¹	P-int
Age			0.04			0.27
<60 yrs	228/31903	1.02 (0.82, 1.27)		171/31903	1.02 (0.79, 1.32)	
≥60 yrs	955/54316	1.29 (1.16, 1.44)		1004/54316	1.20 (1.07, 1.34)	
Sex			0.87			0.04
Men	792/36651	1.21 (1.07, 1.36)		653/36651	1.27 (1.11, 1.44)	
Women	391/49568	1.26 (1.06, 1.49)		522/49568	1.04 (0.88, 1.23)	
Race			0.81			0.20
White	1144/83577	1.23 (1.12, 1.36)		1145/83577	1.18 (1.07, 1.31)	
Non-white	39/2642	1.14 (0.70, 1.86)		30/2642	0.76 (0.38, 1.54)	
Average sleep duration			0.46			0.0003
<7 hrs	483/29488	1.12 (0.99, 1.27)		416/29488	1.01 (0.87, 1.17)	
7-8 hrs	486/39890	1.24 (1.03, 1.50)		513/39890	1.26 (1.05, 1.51)	
>8 hrs	214/16841	1.34 (0.95, 1.87)		246/16841	1.73 (1.32, 2.27)	
Family history of CVD			0.005			0.75
No	363/34288	1.00 (0.82, 1.22)		405/34288	1.15 (0.97, 1.34)	
Yes	820/51931	1.33 (1.19, 1.49)		770/51931	1.18 (1.04, 1.34)	
PRS ²			0.22			0.79
Low	198/28033	1.41 (1.14, 1.76)		318/28033	1.00 (0.80, 1.25)	
Medium	358/28034	1.29 (1.08, 1.54)		373/28035	1.34 (1.13, 1.58)	
High	599/28034	1.13 (0.98, 1.31)		456/28033	1.14 (0.96, 1.35)	

Supplementary Table 5. Subgroup analysis of the association between accelerometer-measured sleep duration irregularity and risk of myocardial infarction and stroke in the UK Biobank

¹Adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD ²Among 84101 participants with genotyping information with additional adjustment of the first three genetic principal components Supplemental Figure 1. Risk of incident MI (a) or stroke (b) according to joint categories of sleep duration irregularity and polygenic risk score for MI or stroke. Estimates adjusted for age, sex, race, Townsend deprivation index, work schedules, family history of CVD, and the first three genetic principal components.

(a) MI







Supplemental Figure 2. Risk of incident MI (a) or stroke (b) according to joint categories of sleep duration irregularity and average sleep duration. Estimates adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD.

(a) MI





